ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,868.55
-0.22%
Dow Jones
42,392.27
0.00%
US Dollar vs MXN
20.6504
0.21%
Brent Oil
75.77
-0.11%
Bitcoin
96,666.62
-0.24%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Atea Pharmaceuticals Inc (AVIR)

  7. Atea Pharmaceuticals Inc (AVIR) Noticias

AVIR

Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AVIR
FechaHoraFuenteTítuloSímboloCompañía
16/12/202404:00GlobeNewswire Inc.Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic PartnershipsNASDAQ:AVIRAtea Pharmaceuticals Inc
04/12/202406:00GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)NASDAQ:AVIRAtea Pharmaceuticals Inc
26/11/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
19/11/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AVIRAtea Pharmaceuticals Inc
15/11/202410:00GlobeNewswire Inc.Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
07/11/202415:41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVIRAtea Pharmaceuticals Inc
07/11/202415:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVIRAtea Pharmaceuticals Inc
07/11/202415:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
31/10/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
30/10/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
19/09/202415:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
13/09/202406:00GlobeNewswire Inc.Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
28/08/202406:00GlobeNewswire Inc.Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation PathwayNASDAQ:AVIRAtea Pharmaceuticals Inc
07/08/202415:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
31/07/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
18/06/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
05/06/202406:00GlobeNewswire Inc.Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
04/06/202415:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AVIRAtea Pharmaceuticals Inc
29/05/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
22/05/202406:00GlobeNewswire Inc.Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202415:05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
07/05/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
29/04/202406:00GlobeNewswire Inc.Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
27/03/202406:00GlobeNewswire Inc.Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsNASDAQ:AVIRAtea Pharmaceuticals Inc
28/02/202415:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
21/02/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
08/01/202415:05GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
03/01/202406:00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
13/11/202306:00GlobeNewswire Inc.Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202315:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AVIR

Su Consulta Reciente

COIN
ETHUSD
Ethereum
NYSE
VZ
Verizon Communications
AMEX
XLE
Energy Select Sector SPDR
NYSE
MCD
McDonalds
SPI
SP500
S&P 500
COIN
ADAUSD
Cardano
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AMZN
Amazon.com
NYSE
AXP
American Express
CCOM
US30
US 30
NYSE
MRK
Merck
FX
EURUSD
Euro vs US Dollar
CCOM
SILVER
SILVER
COIN
AVAXUSD
Avalanche
AMEX
SPY
SPDR S&P 500
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados